Clinical comparison · Menopause & vasomotor symptoms · Updated 2026-07-02
Low-dose paroxetine is a non-hormonal SSRI approved for hot flashes; estradiol is hormone therapy. This table reproduces labeled and trial-reported facts verbatim, per cell. Their trials differ in design and endpoints, so the numbers are not a head-to-head. The page states facts only and does not recommend an option.
Every value below is reproduced verbatim from an FDA prescribing-information document or a published clinical trial, and each cell links to its source. This page does not rank the two options, does not declare one safer or more effective, and is not medical advice.
| Dimension | Low-dose paroxetine (Brisdelle) | Estradiol |
|---|---|---|
| Drug class | SSRI (paroxetine mesylate 7.5 mg) — non-hormonal[1] | Estrogen (bioidentical 17-beta-estradiol)[2] |
| FDA-approved use | Moderate-to-severe vasomotor symptoms of menopause[1] | Moderate-to-severe vasomotor symptoms; other menopausal indications[3] |
| Pivotal VMS efficacy | VMS frequency reduced by a median 4.3/day at week 4 vs 3.1 placebo (Brisdelle Study 1)[1] | Estrogen reduces hot-flash frequency by ~75% vs placebo (class data)[2] |
| Serious/boxed warning | SSRI class warning for suicidal thoughts in adults under 25[1] | No boxed warning; VTE and stroke are serious risks (route-dependent)[2] |
| Endometrial protection needed | Not applicable — non-hormonal[1] | Added progestogen required if uterus present[2] |
| Pregnancy | Contraindicated in pregnancy (FDA category X)[1] | Contraindicated in pregnancy (FDA category X)[3] |
What the trials measured
The pivotal Brisdelle trial (Study 1, published by Simon et al. 2013) measured change in daily moderate-to-severe hot-flash frequency for low-dose paroxetine (a median 4.3/day reduction at week 4 vs 3.1 with placebo; treatment difference 1.2/day). The estrogen figure is a class-level percentage reduction summarized in the NAMS 2022 statement — a different metric and evidence base. FDA Brisdelle PI
No. Low-dose paroxetine (Brisdelle) is an SSRI dosed at 7.5 mg and is non-hormonal, whereas estradiol is estrogen hormone therapy (FDA labels; NAMS 2022).
No. Because it is non-hormonal, it does not require a progestogen. Estradiol requires added progestogen if you have a uterus (NAMS 2022).
Editorial reviews from ClearHormones of telehealth providers in this category. These are not treatment recommendations, and prescribing decisions rest with a licensed clinician.